GSK Plans to Give Away Free Vaccines to Low-Income Patients

It has been reported that leading pharmaceutical company Glaxo SmithKline has extended its plan to offer complimentary medicines to low-income and uninsured patients aged 19 and above for vaccination.

It has been said that women between the ages of 19 to 25 will also be provided free doses of GSK's vaccine for cervical cancer.

Adam Searing, Project Director of the N. C. Justice Center's Health Access Coalition said, "I think it's a good thing they are doing it".


Dutch Health Ministry Intends to Sell Back Swine Flu Vaccine Doses

The Dutch Health Ministry has intended to sell back its 21 million unexploited H1N1 flu vaccine doses, as the Government doesn't find its requirement anymore.

The Health Ministry has been advancing to GlaxoSmithKline and Novartis for the selling back those doses.

However, the Ministry has refused to provide the exact details of the cost of these doses, as of now.

When the Swine Flu Pandemic was at its peak, the Dutch Government had ordered more than 34 million doses of the tamiflu.


GSK Cease Neurological Research

GlaxoSmithKline PLC are planning to abandon the traditional "white pill and Western markets" strategy, and are looking to make forays into the field of diseases for which it believes it can develop more valuable drugs.


GlaxoSmithKline to stop antidepressant research

Pharmaceuticals giant GlaxoSmithKline has announced that it would stop research work into antidepressant medicines to focus on more valuable drugs.

Chief executive Andrew Witty said the company would stop discovery research in selected areas, including pain and depression. The company also has plans to set up a new research unit for rare diseases.

The company expects to save as much as £500 million annually by 2012 by cutting costs.


GlaxoSmithKline Announces to Sack 4,000 jobs

GlaxoSmithKline has fasten its belt on the track of rival AstraZeneca by announcing thousands of job cuts when it updates on profits this week.

The giant, will announce plans on Thursday for further restructuring with the loss of 4,000 jobs out of its 99,000 global workforce, of which nearly half will be in GSK's research and development centres.



Subscribe to RSS - GlaxoSmithKline